BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jin S, Wang Q, Wu H, Pang D, Xu S. Oncolytic viruses for triple negative breast cancer and beyond. Biomark Res 2021;9:71. [PMID: 34563270 DOI: 10.1186/s40364-021-00318-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Li L, Zhang F, Liu Z, Fan Z. Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. Cancers (Basel) 2023;15. [PMID: 36612317 DOI: 10.3390/cancers15010321] [Reference Citation Analysis]
2 Liu H, Wen Z, Chen H, Yang Z, Le Z, Liu Z, Chen Y, Liu L. Nanoadjuvants Actively targeting lymph node conduits and blocking tumor invasion in lymphatic vessels. J Control Release 2022;352:497-506. [PMID: 36341931 DOI: 10.1016/j.jconrel.2022.10.053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hooda-nehra A, L. Smith T, I. Ferrer A, I. Staquicini F, Arap W, Pasqualini R, Rameshwar P. Targeted Regulation and Cellular Imaging of Tumor-Associated Macrophages in Triple-Negative Breast Cancer: From New Mechanistic Insights to Candidate Translational Applications. Macrophages celebrating 140 years of discovery [Working Title] 2022. [DOI: 10.5772/intechopen.105654] [Reference Citation Analysis]
4 Carter ME, Koch A, Lauer UM, Hartkopf AD. Clinical Trials of Oncolytic Viruses in Breast Cancer. Front Oncol 2021;11:803050. [PMID: 35004328 DOI: 10.3389/fonc.2021.803050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]